Open Access

[Corrigendum] Enhanced antitumor activity by the combination of dasatinib and combretastatin A‑4 in vitro and in vivo

  • Authors:
    • Chong Zhang
    • Shuang-Shuang Zhou
    • Xiang-Rong Li
    • Bao-Ming Wang
    • Neng-Ming Lin
    • Lin-Yi Feng
    • Da-Yong Zhang
    • Li-Huang Zhang
    • Jun-Bo Wang
    • Jian-Ping Pan
  • View Affiliations

  • Published online on: July 24, 2024     https://doi.org/10.3892/or.2024.8783
  • Article Number: 124
  • Copyright : © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Article

Oncol Rep 29: [Related article:] 2275–2282, 2013; DOI: 10.3892/or.2013.2405

Following the publication of this article, an interested reader drew to the authors' attention that the flow cytometric (FCM) plots in Fig. 2A on p. 2278 showing the ‘Dasatinib’ and ‘CA-4’ experiments were duplicates of each other. After having re-examined their original data, and due to the overall similarity of the data, the authors have realized that these data were inadvertently assembled incorrectly in the figure. They realize that they also made a further mistake regarding the writing of the ratios of mitochondrial membrane-depolarized HO-8910 cells for these FCM plots (essentially, these were written the wrong way around): The percentage of mitochondrial membrane-depolarized HO-8910 cells should have been written as 22.50% for the dasatinib-treated cells (the centre-left FCM plot) and 15.71% for the CA-4-treated cells (centre-right plot).

A revised version of Fig. 2 now showing alternative data for the FCM experiments shown in Fig. 2A, is shown on the next page. Note that the errors made in terms of assembling the data in Fig. 2A did not greatly affect either the results or the conclusions reported in this paper, and all the authors agree with the publication of this corrigendum. The authors regret that these errors went unnoticed prior to the publication of their article, and are grateful to the Editor of Oncology Reports for granting them this opportunity to publish a corrigendum. Furthermore, they apologize to the readership for any inconvenience caused.

Related Articles

Journal Cover

October-2024
Volume 52 Issue 4

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhang C, Zhou S, Li X, Wang B, Lin N, Feng L, Zhang D, Zhang L, Wang J, Pan J, Pan J, et al: [Corrigendum] Enhanced antitumor activity by the combination of dasatinib and combretastatin A‑4 <em>in vitro</em> and <em>in vivo</em>. Oncol Rep 52: 124, 2024.
APA
Zhang, C., Zhou, S., Li, X., Wang, B., Lin, N., Feng, L. ... Pan, J. (2024). [Corrigendum] Enhanced antitumor activity by the combination of dasatinib and combretastatin A‑4 <em>in vitro</em> and <em>in vivo</em>. Oncology Reports, 52, 124. https://doi.org/10.3892/or.2024.8783
MLA
Zhang, C., Zhou, S., Li, X., Wang, B., Lin, N., Feng, L., Zhang, D., Zhang, L., Wang, J., Pan, J."[Corrigendum] Enhanced antitumor activity by the combination of dasatinib and combretastatin A‑4 <em>in vitro</em> and <em>in vivo</em>". Oncology Reports 52.4 (2024): 124.
Chicago
Zhang, C., Zhou, S., Li, X., Wang, B., Lin, N., Feng, L., Zhang, D., Zhang, L., Wang, J., Pan, J."[Corrigendum] Enhanced antitumor activity by the combination of dasatinib and combretastatin A‑4 <em>in vitro</em> and <em>in vivo</em>". Oncology Reports 52, no. 4 (2024): 124. https://doi.org/10.3892/or.2024.8783